710GO is a next-generation, first-in-class oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce healthier, more durable weight loss May 28, 2026 -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced that the first patients were dosed in the first-in-human Phase 1 clinical trial evaluating 710GO, a novel oral dual melanoc

May 28, 2026 -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease (CAD). Lately, Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established a world-leading anticoagulation/antithrombotic

EPICS-III trial Phase 3 results demonstrated significant biochemical response; data to be presented as a late-breaking presentation at EASL Congress 2026. US FDA granted Priority Review and assigned PDUFA target action date of November 27, 2026. In the EPICS-III trial Phase 3 results, saroglitazar met the primary endpoint of biochemical response, with 56.7% of patients treated with saroglitazar achieving biochemical response versus 9.8% of patients receiving placebo, a treatment difference of 4

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood – May 28, 2026 --Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, to

SNTX-2643 is a novel, investigational, state-selective serotonin transporter modulator being developed for anxiety disorders Company also announces appointment of Cole Brown, M.D., as Chief Medical Officer and formation of a Clinical Advisory Board May 27, 2026 -- Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced that it will present th

Strategic partnership combines NorthStar's commercial-scale radioisotope production capabilities with QSA Global's expertise in lifecycle management of Radium-226 (Ra-226), the starting material for Ac-225 production Agreement aims to strengthen NorthStar's no carrier added (n.c.a) Ac-225 supply chain by establishing a reliable, closed-loop source of high-purity Ra-226 target materials May 27, 2026 -- QSA Global, Inc., a global leader in specialized radioactive source manufacturing and medical

Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents May 27, 2026 -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance o

Collaboration connects translational oncology research and clinical development with comprehensive multi-omics profiling May 27, 2026 -- Panome Bio, a leading multi-omics contract research organization (CRO) and CLIA-certified laboratory, and TD2 Oncology, a globally recognized oncology-focused CRO specializing in preclinical and clinical drug development, today announced an expansion of their strategic partnership. The collaboration establishes a coordinated framework that gives researchers ac

88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment Cognitive function scores improved or remained stable throughout the course of treatment with IBTROZI IBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breath May 27, 2026 -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment,

May 27, 2026 -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million. In this private pla